Publication | Open Access
OA05.05 Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Refractory SCLC: A Subgroup Analysis of a Phase 1/2 Study
39
Citations
0
References
2023
Year
Refractory SclcPhase 1/2Clinical TherapeuticPharmacotherapyDermatologyMedicineOa05.05 Ifinatamab Deruxtecan
No additional data available for this publication yet. Check back later!